Cargando…

HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation

BACKGROUND: Atrial fibrillation is a progressive arrhythmia, the exact mechanism underlying the progressive nature of recurrent AF episodes is still unknown. Recently, it was found that key players of the protein quality control system of the cardiomyocyte, i.e. Heat Shock Proteins, protect against...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanters, Eva A. H., van Marion, Denise M. S., Kik, Charles, Steen, Herman, Bogers, Ad J. J. C., Allessie, Maurits A., Brundel, Bianca J. J. M., de Groot, Natasja M. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635598/
https://www.ncbi.nlm.nih.gov/pubmed/26541406
http://dx.doi.org/10.1186/s12967-015-0714-7
_version_ 1782399529223454720
author Lanters, Eva A. H.
van Marion, Denise M. S.
Kik, Charles
Steen, Herman
Bogers, Ad J. J. C.
Allessie, Maurits A.
Brundel, Bianca J. J. M.
de Groot, Natasja M. S.
author_facet Lanters, Eva A. H.
van Marion, Denise M. S.
Kik, Charles
Steen, Herman
Bogers, Ad J. J. C.
Allessie, Maurits A.
Brundel, Bianca J. J. M.
de Groot, Natasja M. S.
author_sort Lanters, Eva A. H.
collection PubMed
description BACKGROUND: Atrial fibrillation is a progressive arrhythmia, the exact mechanism underlying the progressive nature of recurrent AF episodes is still unknown. Recently, it was found that key players of the protein quality control system of the cardiomyocyte, i.e. Heat Shock Proteins, protect against atrial fibrillation progression by attenuating atrial electrical and structural remodeling (electropathology). HALT & REVERSE aims to investigate the correlation between electropathology, as defined by endo- or epicardial mapping, Heat Shock Protein levels and development or recurrence of atrial fibrillation following pulmonary vein isolation, or electrical cardioversion or cardiothoracic surgery. STUDY DESIGN: This study is a prospective observational study. Three separate study groups are defined: (1) cardiothoracic surgery, (2) pulmonary vein isolation and (3) electrical cardioversion. An intra-operative high-resolution epicardial (group 1) or endocardial (group 2) mapping procedure of the atria is performed to study atrial electropathology. Blood samples for Heat Shock Protein determination are obtained at baseline and during the follow-up period at 3 months (group 2), 6 months (groups 1 and 2) and 1 year (group 1 and 2). Tissue samples of the right and left atrial appendages in patients in group 1 are analysed for Heat Shock Protein levels and for tissue characteristics. Early post procedural atrial fibrillation is detected by continuous rhythm monitoring, whereas late post procedural atrial fibrillation is documented by either electrocardiogram or 24-h Holter registration. CONCLUSION: HALT & REVERSE aims to identify the correlation between Heat Shock Protein levels and degree of electropathology. The study outcome will contribute to novel diagnostic tools for the early recognition of clinical atrial fibrillation. Trial Registrations: Rotterdam Medical Ethical Committee MEC-2014-393, Dutch Trial Registration NTR4658
format Online
Article
Text
id pubmed-4635598
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46355982015-11-07 HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation Lanters, Eva A. H. van Marion, Denise M. S. Kik, Charles Steen, Herman Bogers, Ad J. J. C. Allessie, Maurits A. Brundel, Bianca J. J. M. de Groot, Natasja M. S. J Transl Med Protocol BACKGROUND: Atrial fibrillation is a progressive arrhythmia, the exact mechanism underlying the progressive nature of recurrent AF episodes is still unknown. Recently, it was found that key players of the protein quality control system of the cardiomyocyte, i.e. Heat Shock Proteins, protect against atrial fibrillation progression by attenuating atrial electrical and structural remodeling (electropathology). HALT & REVERSE aims to investigate the correlation between electropathology, as defined by endo- or epicardial mapping, Heat Shock Protein levels and development or recurrence of atrial fibrillation following pulmonary vein isolation, or electrical cardioversion or cardiothoracic surgery. STUDY DESIGN: This study is a prospective observational study. Three separate study groups are defined: (1) cardiothoracic surgery, (2) pulmonary vein isolation and (3) electrical cardioversion. An intra-operative high-resolution epicardial (group 1) or endocardial (group 2) mapping procedure of the atria is performed to study atrial electropathology. Blood samples for Heat Shock Protein determination are obtained at baseline and during the follow-up period at 3 months (group 2), 6 months (groups 1 and 2) and 1 year (group 1 and 2). Tissue samples of the right and left atrial appendages in patients in group 1 are analysed for Heat Shock Protein levels and for tissue characteristics. Early post procedural atrial fibrillation is detected by continuous rhythm monitoring, whereas late post procedural atrial fibrillation is documented by either electrocardiogram or 24-h Holter registration. CONCLUSION: HALT & REVERSE aims to identify the correlation between Heat Shock Protein levels and degree of electropathology. The study outcome will contribute to novel diagnostic tools for the early recognition of clinical atrial fibrillation. Trial Registrations: Rotterdam Medical Ethical Committee MEC-2014-393, Dutch Trial Registration NTR4658 BioMed Central 2015-11-05 /pmc/articles/PMC4635598/ /pubmed/26541406 http://dx.doi.org/10.1186/s12967-015-0714-7 Text en © Lanters et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Protocol
Lanters, Eva A. H.
van Marion, Denise M. S.
Kik, Charles
Steen, Herman
Bogers, Ad J. J. C.
Allessie, Maurits A.
Brundel, Bianca J. J. M.
de Groot, Natasja M. S.
HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation
title HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation
title_full HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation
title_fullStr HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation
title_full_unstemmed HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation
title_short HALT & REVERSE: Hsf1 activators lower cardiomyocyt damage; towards a novel approach to REVERSE atrial fibrillation
title_sort halt & reverse: hsf1 activators lower cardiomyocyt damage; towards a novel approach to reverse atrial fibrillation
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635598/
https://www.ncbi.nlm.nih.gov/pubmed/26541406
http://dx.doi.org/10.1186/s12967-015-0714-7
work_keys_str_mv AT lantersevaah haltreversehsf1activatorslowercardiomyocytdamagetowardsanovelapproachtoreverseatrialfibrillation
AT vanmariondenisems haltreversehsf1activatorslowercardiomyocytdamagetowardsanovelapproachtoreverseatrialfibrillation
AT kikcharles haltreversehsf1activatorslowercardiomyocytdamagetowardsanovelapproachtoreverseatrialfibrillation
AT steenherman haltreversehsf1activatorslowercardiomyocytdamagetowardsanovelapproachtoreverseatrialfibrillation
AT bogersadjjc haltreversehsf1activatorslowercardiomyocytdamagetowardsanovelapproachtoreverseatrialfibrillation
AT allessiemauritsa haltreversehsf1activatorslowercardiomyocytdamagetowardsanovelapproachtoreverseatrialfibrillation
AT brundelbiancajjm haltreversehsf1activatorslowercardiomyocytdamagetowardsanovelapproachtoreverseatrialfibrillation
AT degrootnatasjams haltreversehsf1activatorslowercardiomyocytdamagetowardsanovelapproachtoreverseatrialfibrillation